These findings suggest an ETA-selective antagonist would have a therapeutic advantage over a mixed antagonist in renal disease, and indeed the small number of acute studies directly comparing the peptide antagonists BQ123 versus BQ788 suggest ETA blockade, sparing ETB, may be beneficial. The gene discussed is EDNRA; the disease is kidney disorder.